June 17th – Birmingham, Michigan – CitySide Ventures announces adding BioSense to its portfolio of companies.
Birmingham Angels, a CitySide’s Angels syndicate of angel investors, just closed a round of investment in BioSense.
BioSense has developed a patented non-contact EKG system that can read the EKG through covers and clothing. This passive non-contact system enables proactive diagnostics of the many health conditions that are available from the more than 480 biomarkers in the EKG. Current EKG monitoring uses contacts with adhesives and they often create issues when removed, don’t keep contact well and can cause infections at the site when removed. There are compelling needs for this technology in neonatal ICU’s and with burn patients, etc. Another promising application is with monitoring of hospital staff for changes in their EKG readings as early warning for a virus onset. A study is already underway with a key hospital in the midwest.
“I am very excited about the promising future this technology offers in multiple market segments” – David Weaver – Chief Investment Officer at CitySide Ventures
Birmingham Angels’ goal is to become a premier Investment group committed to taking Michigan Angel investing to a new level by building a network of active, progressive and innovative investors committed to turning Michigan into a powerhouse startup ecosystem.
For more information about Birmingham Angels please visit us at: https://citysideventures.com/birmingham-angels/
If you are an accredited investor and would like to schedule a private meeting,
please complete the following request form: https://citysideventures.com/birmingham-angels-individual/
or contact us: email@example.com; 248. 535.1306